| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Gerald T Nepom | Q38546281 |
| P2093 | author name string | Mario R Ehlers | |
| Dawn E Smilek | |||
| P2860 | cites work | Regulation of adaptive immunity; the role of interleukin-10 | Q21131215 |
| Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse | Q24290693 | ||
| An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains | Q24313206 | ||
| Aire and T cell development | Q24621103 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity | Q24643886 | ||
| Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction | Q24650734 | ||
| Molecular mechanisms for adaptive tolerance and other T cell anergy models | Q24671646 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation | Q24678846 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Positional cloning of the APECED gene | Q28116470 | ||
| Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor | Q28144319 | ||
| Aire deficient mice develop multiple features of APECED phenotype and show altered immune response | Q28202432 | ||
| PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2 | Q28202803 | ||
| Projection of an immunological self shadow within the thymus by the aire protein | Q28207164 | ||
| CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones | Q28209894 | ||
| Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis | Q28270369 | ||
| Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) | Q28280453 | ||
| Genetics, pathogenesis and clinical interventions in type 1 diabetes | Q28281029 | ||
| Type 1 diabetes: translating mechanistic observations into effective clinical outcomes | Q28287737 | ||
| Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial | Q28304807 | ||
| Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group | Q29616063 | ||
| Regulatory T cells and immune tolerance | Q29616864 | ||
| IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors | Q29618425 | ||
| The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 | Q29619324 | ||
| T cell exhaustion | Q29620463 | ||
| Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. | Q33892424 | ||
| Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice | Q33911256 | ||
| Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo | Q33924186 | ||
| Regulatory T cells as therapeutic targets in rheumatoid arthritis | Q37607071 | ||
| A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis | Q37611832 | ||
| Novel targeted therapies for autoimmunity | Q37614638 | ||
| Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin | Q37622936 | ||
| Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial | Q37642554 | ||
| Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis | Q37679881 | ||
| Defining dendritic cells by conditional and constitutive cell ablation | Q37700824 | ||
| Therapeutic antibodies for autoimmunity and inflammation | Q37736260 | ||
| Considerations When Submitting Nanotherapeutics to FDA/CDER for Regulatory Review | Q37813524 | ||
| Toll-like receptor driven B cell activation in the induction of systemic autoimmunity | Q37838577 | ||
| Innate immunity in transplant tolerance and rejection | Q37864689 | ||
| Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family | Q37864700 | ||
| Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success | Q37977225 | ||
| Beyond transitional selection: New roles for BLyS in peripheral tolerance | Q37983058 | ||
| Lymphodepletion and homeostatic proliferation: implications for transplantation | Q37993873 | ||
| Integration of B cell responses through Toll-like receptors and antigen receptors | Q37994060 | ||
| Autologous regulatory T cells for the treatment of type 1 diabetes | Q38030480 | ||
| Coinhibitory molecules in autoimmune diseases. | Q38045307 | ||
| Regulation of TLR7/9 signaling in plasmacytoid dendritic cells | Q38058240 | ||
| The ONE Study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocyte-derived cells | Q38078099 | ||
| Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. | Q38078565 | ||
| Trials in type 1 diabetes: Antigen-specific therapies | Q38089387 | ||
| The plasticity and stability of regulatory T cells. | Q50987847 | ||
| Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. | Q51778586 | ||
| Molecular signature of CD8+ T cell exhaustion during chronic viral infection. | Q51970485 | ||
| Mechanisms of tolerance. | Q53906830 | ||
| A role for TCR affinity in regulating naive T cell homeostasis. | Q54040597 | ||
| A Theory of Self-Nonself Discrimination: Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively | Q55888521 | ||
| Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function | Q57491711 | ||
| Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial | Q57911995 | ||
| Amelioration of Autoimmune Encephalomyelitis by Myelin Basic Protein Synthetic Peptide-Induced Anergy | Q67464153 | ||
| Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes | Q71707114 | ||
| Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity | Q72105878 | ||
| Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand | Q73035541 | ||
| The diabetes-prone BB rat carries a frameshift mutation in Ian4, a positional candidate of Iddm1 | Q74181057 | ||
| Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference | Q77626838 | ||
| Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent | Q78025335 | ||
| Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis | Q78404404 | ||
| TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells | Q80427855 | ||
| IMMUNOGENETIC CONSEQUENCES OF VASCULAR ANASTOMOSES BETWEEN BOVINE TWINS | Q80949985 | ||
| Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling | Q81299785 | ||
| TGF-β puts the brakes on homeostatic proliferation | Q84411791 | ||
| Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group | Q84567639 | ||
| Good guys gone bad: exTreg cells promote autoimmune arthritis | Q87049812 | ||
| Anti-cytokine therapies in T1D: Concepts and strategies | Q38091182 | ||
| Biological therapies for rheumatoid arthritis: progress to date | Q38096206 | ||
| Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity | Q38116353 | ||
| A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application | Q38163290 | ||
| Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes | Q38333256 | ||
| Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy | Q38624477 | ||
| Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens | Q41170875 | ||
| Anergic responses characterize a large fraction of human autoreactive naive B cells expressing low levels of surface IgM. | Q42104679 | ||
| Cell-based therapeutics: the next pillar of medicine | Q42613853 | ||
| Antibodies to watch in 2013: Mid-year update | Q42724515 | ||
| Regulatory T cells: stability revisited | Q42786356 | ||
| Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity | Q42972501 | ||
| Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study | Q44464975 | ||
| Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis | Q44688981 | ||
| Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study | Q45747892 | ||
| Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. | Q45997264 | ||
| When mice mislead. | Q46007268 | ||
| A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. | Q46273482 | ||
| Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice | Q46345979 | ||
| Personalizing medicine for autoimmune and inflammatory diseases | Q46477760 | ||
| Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells | Q46686118 | ||
| Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. | Q47365613 | ||
| Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy | Q47382060 | ||
| Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis | Q47581510 | ||
| Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity | Q36282394 | ||
| Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial | Q36292592 | ||
| Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo | Q36353340 | ||
| Evidence for the clonal abortion theory of B-lymphocyte tolerance | Q36357840 | ||
| Receptor editing: an approach by autoreactive B cells to escape tolerance | Q36361497 | ||
| T cell regulation as a side effect of homeostasis and competition | Q36370619 | ||
| Involvement of avidity for major histocompatibility complex in homeostasis of naive and memory T cells | Q36370660 | ||
| In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes | Q36399048 | ||
| Defective B cell tolerance checkpoints in systemic lupus erythematosus | Q36402748 | ||
| Alternative approaches to myeloid suppressor cell therapy in transplantation: comparing regulatory macrophages to tolerogenic DCs and MDSCs | Q36578322 | ||
| Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. | Q36654124 | ||
| Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis | Q36661068 | ||
| IL-10-producing regulatory B cells (B10 cells) in autoimmune disease | Q36760499 | ||
| Autoimmunity risk alleles: hotspots in B cell regulatory signaling pathways. | Q36793513 | ||
| A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models | Q36802757 | ||
| Specific peripheral B cell tolerance defects in patients with multiple sclerosis | Q36890946 | ||
| Advances in targeting cell surface signalling molecules for immune modulation | Q36973787 | ||
| IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells | Q36985100 | ||
| Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation | Q37065897 | ||
| Expansion of human regulatory T-cells from patients with type 1 diabetes | Q37105331 | ||
| IL-7 is critical for homeostatic proliferation and survival of naive T cells | Q37113213 | ||
| The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus | Q37170754 | ||
| Human regulatory T cells: role in autoimmune disease and therapeutic opportunities | Q37211296 | ||
| Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders | Q37251153 | ||
| Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology | Q37257207 | ||
| Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo | Q37312884 | ||
| The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial | Q37374964 | ||
| Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response | Q37552169 | ||
| ??? | Q28255051 | ||
| Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. | Q33977505 | ||
| A prescription for human immunology | Q34001827 | ||
| Redefining chronic viral infection | Q34018497 | ||
| Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential | Q34082782 | ||
| Regulatory T cells and Foxp3 | Q34177949 | ||
| Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells | Q34189120 | ||
| Lebrikizumab treatment in adults with asthma | Q34205683 | ||
| Actively acquired tolerance of foreign cells | Q34233179 | ||
| The role of interleukin-2 during homeostasis and activation of the immune system | Q34255232 | ||
| Clonal deletion of autoreactive B lymphocytes in bone marrow chimeras | Q34313426 | ||
| Autoimmune diseases. | Q34325674 | ||
| The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders | Q34349150 | ||
| A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes | Q34421851 | ||
| Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate | Q34547988 | ||
| Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial | Q34559671 | ||
| Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice | Q34583970 | ||
| How tolerogenic dendritic cells induce regulatory T cells | Q34631825 | ||
| Biologic therapy for autoimmune diseases: an update | Q34655597 | ||
| Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. | Q34778730 | ||
| Challenges in the pursuit of immune tolerance. | Q34974448 | ||
| Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. | Q35175866 | ||
| The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans | Q35187072 | ||
| Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene | Q35785496 | ||
| Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells | Q35867877 | ||
| Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes | Q35891952 | ||
| B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels | Q36049625 | ||
| The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance | Q36133008 | ||
| Cellular and genetic mechanisms of self tolerance and autoimmunity | Q36148399 | ||
| American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis | Q36221407 | ||
| Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. | Q36228158 | ||
| BAFF and MyD88 signals promote a lupuslike disease independent of T cells | Q36229560 | ||
| CTLA-4 is a second receptor for the B cell activation antigen B7 | Q36230356 | ||
| The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients | Q36245889 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| autoimmune disease | Q8084905 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 503-513 | |
| P577 | publication date | 2014-05-01 | |
| P1433 | published in | Disease Models & Mechanisms | Q1524006 |
| P1476 | title | Restoring the balance: immunotherapeutic combinations for autoimmune disease | |
| P478 | volume | 7 |
| Q92004305 | Analysis of circulating soluble programmed death 1 (PD-1), neuropilin 1 (NRP-1) and human leukocyte antigen-G (HLA-G) in psoriatic patients |
| Q26801229 | Biomimetic and synthetic interfaces to tune immune responses |
| Q49788177 | CD122 blockade restores immunological tolerance in autoimmune type 1 diabetes via multiple mechanisms |
| Q39282825 | Challenges for the pharmaceutical technical development of protein coformulations. |
| Q57221897 | Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients |
| Q48305722 | Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression. |
| Q40109239 | Colonic perforation in a patient with systemic lupus erythematosus accompanied by cytomegalovirus infection: A case report. |
| Q48684168 | Current and future approaches to the treatment of immunologic diseases: new targets and new therapeutic agents |
| Q38244567 | Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. |
| Q35762695 | Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226. |
| Q38691330 | Expansion of FasL-Expressing CD5+ B Cells in Type 1 Diabetes Patients |
| Q42593469 | From bench to patient: model systems in drug discovery |
| Q36520618 | Immune interventions to preserve β cell function in type 1 diabetes |
| Q88222427 | Non-immune-based treatment for type 1 diabetes: the way to go? |
| Q58129532 | Predicting T cell recognition of MHC class I restricted neoepitopes |
| Q42552506 | Proceedings: Immune Tolerance and Stem Cell Transplantation: A CIRM Mini-Symposium and Workshop Report |
| Q38781734 | Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease |
| Q92354159 | Quantitative Predictive Modelling Approaches to Understanding Rheumatoid Arthritis: A Brief Review |
| Q45030349 | Receptor occupancy by flow cytometry |
| Q28084677 | Solving the puzzle of autoimmunity: critical questions |
| Q36995370 | Strategies for clinical trials in type 1 diabetes |
| Q35836118 | T cells in the control of organ-specific autoimmunity |
| Q38586890 | Targeting memory T cells in type 1 diabetes |
| Q38738124 | The BAFFling effects of rituximab in lupus: danger ahead? |
| Q48265755 | The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial. |
| Q38991057 | The immune system's role in sepsis progression, resolution, and long-term outcome |
Search more.